Stopping renin–angiotensin–aldosterone system inhibitors in kidney disease | Synapse
March 16, 2026Open Access
Stopping renin–angiotensin–aldosterone system inhibitors in kidney disease
Key Points
This review aims to assess the impact of stopping RAS inhibitors on kidney disease outcomes.
Review of existing literature on RASi discontinuation.
Analysis of outcomes related to chronic kidney disease (CKD), hyperkalemia, and acute kidney injury (AKI).
Discontinuation of RASi is linked to worse outcomes in CKD.
Increased prevalence of hyperkalemia after stopping RASi.
Higher incidence of acute kidney injury following RASi cessation.
Abstract
This review highlights outcomes following the discontinuation of RASi, which is generally associated with worse outcomes across the spectrum of CKD, hyperkalemia, and AKI.